Vermeire S, Peeters M, Rutgeerts P
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Hepatogastroenterology. 2000 Jan-Feb;47(31):44-8.
Inflammatory bowel disease, with Crohn's disease and ulcerative colitis as the two main disorders, is a heterogeneous group of disorders of unknown etiology. Clinical initial presentation is sometimes misleading and causing diagnostic delay which may be important. Identification of subgroups of patients on the basis of genetic, immunologic and clinical markers will be important for exact diagnosis, but also for new drug trials. The current diagnosis depends on clinical, radiographic, endoscopic and laboratory data. The introduction of serological markers such as pANCA and ASCA will allow an increase in the diagnostic accuracy at initial diagnosis of inflammatory bowel disease and may play a role in defining subgroups of the disease.
炎症性肠病以克罗恩病和溃疡性结肠炎为两种主要病症，是一组病因不明的异质性疾病。临床初始表现有时具有误导性，会导致诊断延迟，这可能很重要。基于遗传、免疫和临床标志物识别患者亚组不仅对准确诊断很重要，对新药试验也很重要。目前的诊断依赖于临床、影像学、内镜和实验室数据。诸如抗中性粒细胞胞浆抗体（pANCA）和抗酿酒酵母抗体（ASCA）等血清学标志物的引入将提高炎症性肠病初始诊断的准确性，并可能在界定该疾病的亚组方面发挥作用。
